Recombinant toxin DAB389EGF is cytotoxic to human pancreatic cancer cells

Expert Opinion on Biological Therapy

Volumn 3, Issue 7, 2003, Pages 1173-1180

  Mishra, Girish ^a   Lu, Tie Fu ^a   Frankel, Ardiur E ^a  

^a WAKE FOREST SCHOOL OF MEDICINE   (United States)

Author keywords

Diphtheria fusion protein; Endoscopic ultrasound; Epidermal growth factor receptor; Pancreatic adenocarcinoma

Indexed keywords

ANTINEOPLASTIC AGENT; DIPHTHERIA TOXIN; EPIDERMAL GROWTH FACTOR; EPIDERMAL GROWTH FACTOR RECEPTOR; GEMCITABINE; HYBRID PROTEIN; MATRIX METALLOPROTEINASE; RECOMBINANT PROTEIN; DAB389EGF PROTEIN, HUMAN;

ADENOVIRUS; ANIMAL MODEL; CANCER CELL; CANCER DIAGNOSIS; CANCER STAGING; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; CYTOTOXICITY; DIAGNOSTIC ACCURACY; DRUG DELIVERY SYSTEM; DRUG SYNTHESIS; ENDOSCOPIC ECHOGRAPHY; ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY; ENDOSCOPIC ULTRASOUND GUIDED FINE NEEDLE INJECTION; HUMAN; HUMAN CELL; MIXED LYMPHOCYTE CULTURE; MOUSE; MULTICENTER STUDY; NONHUMAN; PANCREAS ADENOCARCINOMA; PANCREAS CANCER; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; REVIEW; TREATMENT OUTCOME; ULTRASOUND; ADENOCARCINOMA; ANIMAL; ARTICLE; CELL SURVIVAL; DRUG EFFECT; GENETICS; INJECTION; PANCREAS; PANCREAS TUMOR; PATHOLOGY; PROTO ONCOGENE; TUMOR CELL LINE;

ADENOVIRIDAE; ANIMALIA;

ADENOCARCINOMA; ANIMALS; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CELL SURVIVAL; DIPHTHERIA TOXIN; GENES, ERBB-1; HUMANS; INJECTIONS; PANCREAS; PANCREATIC NEOPLASMS; RECOMBINANT FUSION PROTEINS;

EID: 0142119195     PISSN: 14712598     EISSN: None     Source Type: Journal    
DOI: 10.1517/14712598.3.7.1173     Document Type: Review

References (48)

1. JEMAL A, MURRAY T, SAMUELS A, GHAFFOR A, WARD E, THUN MJ: Cancer statistics, 2003. CA Cancer J. Clin. (2003) 53:5-26.
2. DOUGLASS HO JR: Adjuvant therapy for pancreatic cancer. World J. Surg. (1995) 19:270-274.
3. NO AUTHORS LISTED: American Cancer Society Facts and Figures: 1991. American Cancer Society (1991):29.
4. CONNOLLY MM, DAWSON PJ, MICHELASSI F, MOOSSA AR, LOWENSTEIN F: Survival in 1001 patients with carcinoma of the pancreas. Ann. Surg. (1987) 206:366-373.
5. SINGH SM, LONGMIRE WP JR, REBER HA. Surgical palliation for pancreatic cancer. The UCLA experience. Ann. Surg. (1990) 212:132-139.
6. KIMURA W, MORIKANE K, ESAKI Y et al.: Histologic and biologic patterns of microscopic pancreatic ductal adenocarcinomas detected incidentally at autopsy. Cancer (1998) 82:1839-1849.
7. ABBRUZZESE JL: Past and present treatment of pancreatic adenocarcinoma: chemotherapy as a standard treatment modality. Semin. Oncol. (2002) 29(6 Suppl. 20):2-8.
8. EL-RAYES BF, SHIELDS AF, VAITKEVICIUS V, PHILIP PA: Developments in the systemic therapy of pancreatic cancer. Cancer Invest. (2003) 21:73-86.
9. SHUMATE CR, BARON TH: Palliative procedures for pancreatic cancer: when and which one? South. Med. J. (1996) 89:27-32.
10. EL KAMAR FG, GROSSBARD ML, KOZUCH PS: Metastatic pancreatic cancer: emerging strategies in chemotherapy and palliative care. Oncologist (2003) 8:18-34.
11. BUTERA J, MALACHOVSKY M, RATHORE R et al.: Novel approaches in development for the treatment of pancreatic cancer. Front. Biosci. (1998) 3:E226-E229.
12. BRAMHALL SR, ROSEMURGY A, BROWN PD et al.: Marimastat as first-line for patients with unresctable pancreatic cancer: a randomized trial. J. Clin. Oncol. (2001) 19:3447-3455.
13. BRAMHALL SR, SCHULZ J, NEMUNAITIS J et al.: A double-blind placebo-controlled, randomised study comparing gemcitabine and marimastat with gemcitabine and placebo as first line therapy in patients with advanced pancreatic cancer. Br. J. Cancer (2002) 87:161-167.
14. DEMPKE WC: Farnesyltransferase inhibitors-a novel approach in the treatment of advanced pancreatic carcinomas. Anticancer Res. (2003) 23:813-818.
15. VON HOFF DD, BEARS D: New drugs for patients with pancreatic cancer. Curr. Opin. Oncol. (2002) 14:621-627.
16. BRUNS CJ, ELLIS LM, KUNIYASU H et al.: In vivo selection and characterization of metastatic variants from human pancreatic adenocarcinoma by using orthotopic implantation in nude mice. Neoplasia (1999) 1:50-62.
17. YAMANAKE Y, FRIESS H, KOBRIN MS et al.: Coexpression of epidermal growth factor receptor and ligands in human pancreatic cancer is associated with enhanced tumor aggressiveness. Anticancer Res. (1993) 13:565-569.
18. CARRAWAY KL, CANTLEY JC: A neu acquaintance for erbB3 and erbB4: a role for receptor heterodimerisation in growth signalling. Cell (1994) 78:5-8.
19. UEGAKI K, NIO Y, INOUE Y et al: Clinicopathological significance of epidermal growth factor and its receptor in human pancreatic cancer. Anticancer Res. (1997) 17:3841-3847.
20. DONG M, NIO Y, GUO NJ et al.: Epidermal growth factor and its receptor as prognostic indicators in Chinese patients with pancreatic cancer. Anticancer Res. (1998) 18:4613-4639.
21. PRIGENT SA, LEMOINE NR: The type 1 (EGFR related) family of growth factor receptors and their ligands. Prog. Growth Factor Res. (1992) 4:1-24.
22. ULLRICH A, SCHLESSINGER J: Signal transduction by receptors with tyrosine kinase activity. Cell (1990) 61(2):203-212.
23. BRUNS C, HARBISON MT, DAVIS DW: Epidermal growth factor receptor blockade with C225 plus gemcitabine results in regression of human pancreatic carcinoma growing orthotopically in nude mice by antiangiogenic mechanisms. Clin. Cancer Res. (2000) 6:1936-1948.
24. BUCHSBAUM DJ, BONNER JA, GRIZZLE WE et al.: Treatment of pancreatic cancer xenografts with erbitux (IMC-C225) anti-EGFR antibody, gemcitabine, and radiation. Int. J. Radiation Oncology Biol. Phys. (2002) 4:1180-1193.
25. BROOKE JS, CHA JH: Molecular characterization of key diphtheria toxin: receptor interactions. Biochem. Biophys. Res. Commun. (2000) 275:374-381.
26. FALNES PO, SANDVIG K: Penetration of protein toxins into cells. Curr. Opin. Cell Biol. (2000) 12:407-413.
27. VANDERSPEK JC, MURPHY JR: Fusion protein toxins based on diphtheria toxin: selective targeting of growth factor receptors of eukaryotic cells. Methods Enzymol. (2000) 327:239-249.
28. SHAW JP, AKIYOSHI DE, ARRIGO DA et al.: Cytotoxic properties of DAB486EGF and DAB389EGF, epidermal growth factor (EGF) receptor-targeted fusion toxins. J. Biol. Chem. (1991) 266:21118-21124.
29. LIU TF, COHEN KA, RAMAGE JG, WILLINGHAM MC, THORBURN AM, FRANKEL AE: A diphtheria toxin-epidermal growth factor fusion protein is cytotoxic to human glioblastoma multiforme cells. Cancer Res. (2003) 63:1834-1837.
30. COHEN KA, BISSONNETTE R, PURI RK, FRANKEL AE: Novel fusion protein therapy of refractory brain tumors. Curr. Pharm. Biotech. (2003) 4:39-49.
31. AFIFY AM, AL-KHAFAJI BM, KIM B, SCHEIMAN JM: Endoscopic ultrasound-guided fine needle aspiration of the pancreas. Diagnostic utility and accuracy. Acta Cytol. (2003) 47:341-348.
32. ROCHE CJ, HUGHES ML, GARVEY CJ et al.: CT and pathologic assessment of prospective nodal staging in patients with ductal adenocarcinoma of the head of the pancreas. Am. J. Roentgenol. (2003) 180:475-480.
33. KEITH CJ, MILES KA, WONG D: Pancreatic cancer: preliminary experience with sodium iodide fluorodeoxyglucose positron emission tomography in Australia. Australas. Radiol. (2003) 47:17-21.
34. GANDOLFI L, TORRESAN F, SOLMI L, PUCCETTI A: The role of ultrasound in biliary and pancreatic diseases. Eur. J. Ultrasound (2003) 16:141-159.
35. TAMM EP, SILVERMAN PM, CHARNSANGAVEJ C, EVANS DB: Diagnosis, staging and surveillance of pancreatic cancer. Am J Roentgenol (2003) 180:1311-1323.
36. GRESS FG, HAWES RH, SAVIDES TJ et al.: Role of EUS in the preoperative staging of pancreatic cancer: a large single-center experience. Gastrointest. Endosc. (1999) 50:786-791.
37. CHANG KJ, NGUYEN PT, THOMSPSON TA et al.: Phase I clinical trial of allogeneic mixed lymphocyte culture (Cytoimplant) delivered by endoscopic ultrasound-oded fine-needle injection in patients with advanced pancreatic carcinoma. Cancer (2000) 88:1325-1335.
38. HECHT JR, BEDFORD R, ABBRUZZESE JL et al.: A Phase I/II trial of intratumoral endoscopic ultrasound injection of ONYX-015 with intravenous gemcitabine in unresectable pancreatic carcinoma. Clin. Cancer Res. (2003) 9:555-561.
39. GRESS F, MICHAEL H, GELRUD D et al.: EUS-guided fine-needle aspiration of the pancreas: evaluation of pancreatitis as complication. Gastrointest. Endosc. (2002) 56:864-867.
40. O'TOOLE D, PALAZZO L, AROTCARENA R et al.: Assessment of complications of EUS-guided fine-needle aspiration. Gastrointest. Endosc. (2001) 53:470-474.
41. HOTZ HG, REBER HA, HOTZ B et al.: An orthotopic nude mouse model for evaluating pathophysiology and therapy of pancreatic cancer. Pancreas (2003) 26:E89-E98.
42. XIE K, WANG B, SHI Q et al.: Mouse model of metastatic pancreatic adenocarcinoma. Int. J. Gastrointest. Cancer (2001) 29:25-36.
43. TAKAHASHI M, FURUKAWA F, TOYODA K et al.: Effect of various prostaglandin synthesis inhibitors on pancreatic carcinogenesis in hamsters after N-nitrosobis-(2-oxypropyl)amine. Carcinogenesis (1990) 11:393-395.
44. REDDY JK, RAO MS: Pancreatic adenocarcinoma in inbred guinea pigs induced by n-methyl-N-nitrosourea. Cancer Res. (1975) 35:2269-2277.
45. LONGNECKER DS: Animal models of human disease: carcinoma of the pancreas in azaserine-treated rats. Am. J. Pathol. (1981) 105:94-96.
46. FRANKEL AE, BUGGE TH, LIU S, VALLERA DA, LEPPLA SH: Peptide toxins directed the matrix dissolution systems of cancer cells. Protein Peptide Lett. (2002) 9:1-14.
47. NAGAKAWA Y, AOKI T, KASUYA K, TSUCHIDA A, KOYANAGI Y: Histologic features of venous invasion, expression of vascular endothelial growth factor and matrix metalloproteinase-2 and matrix metalloproteinase-9, and the relation with liver metastases in pancreatic cancer. Pancreas (2002) 24:169-178.
48. WANG W, ABBRUZZESE JL, EVANS DB, CHIAO PJ: Overexpression of urokinase-type plasminogen activator in pancreatic adenocarcinoma is regulated by constitutively activated RelA. Oncogene (1999) 18:4554-4563.